Early Toxicity Testing Market Overview:
Global Early Toxicity Testing Market was $614 million and is estimated to reach $1,012 million by 2022, registering a CAGR of 7.3% from 2016 to 2022. Toxins are substances that can adversely affect living organisms. They are present in a variety of products such as food additives, chemicals, pesticides, and cosmetics. During drug development, it was observed that approximately 26% of the products face rejection in the later stages of development due to safety issues. This leads to massive financial losses for many industries, which include pharmaceuticals and food industries. To avoid the financial losses, early toxicity tests are used to remove the toxic component in the product and reduce the risk of late-stage failure. Different types of toxic tests such as acute toxicity tests, neurotoxicity, systemic toxicity, and carcinogenicity are conducted using in vivo and in vitro techniques. These toxicity tests help the companies provide proofs to the regulatory bodies that they are safe for humans and will not adversely affect human health.
Global Early Toxicity Testing Market Segmentation
The global early toxicity testing market is segmented based on technique, end users, and geography. Based on technique, the market is categorized into in vivo, in vitro, and in silico. Based on the type of assay used, in vitro technique is further divided into enzyme toxicity assays, bacterial toxicity assays, cell-based ELISA and western blots, tissues culture assays, receptor binding assays, and other assays. Based on the toxicity end-points, in vitro technique is further segmented into dermal toxicity, systemic toxicity, carcinogenicity, ocular toxicity, skin sensitization and irritation, genotoxicity, neurotoxicity, organ toxicity, and other toxicity endpoints. Based on end-users, the market is segmented into pharmaceuticals industry, diagnostics industry, food industry, chemicals industry, cosmetics industry, and other industries. The market is analyzed based on four regions, namely North America, Europe, Asia-Pacific, and LAMEA.
The market is expected to witness moderate growth during the forecast period, owing to the increase in awareness of the regulatory authorities concerning environment and public health welfare. In addition, replacement of in vivo models with in vitro models and technological advancement in the in vitro and in vivo technique supplement the market growth. As early toxicity tests can help reduce the risk of drug failure in later stages, there is a rise in the demand for early toxicity tests. This has increased investment in the R&D for these products, which help boost the market growth. However, limited awareness about the benefits of early toxicity testing and limitations of preclinical testing are expected to hamper the market growth.
The early toxicity testing market is growing at a steady pace due to the increase in stringency of regulatory authorities regarding environment and public welfare. Furthermore, the use of early toxicity tests reduce the risks of drug failure in later stages of drug development, thus preventing heavy financial losses of the companies. This has led to the growth in the investment for R&D of toxicity testing techniques and emergence of new models & tests to evaluate the toxicity of the substance. For instance, on July 2016, Cyprotex PLC launched an in vitro 3D cellular model that could be used to evaluate cardiotoxicity.
The key players profiled in this report include Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Agilent Technologies Inc., Quest Diagnostics Incorporation, Merck & Co., Inc., Charles River Laboratories International Incorporation, Becton, Dickinson And Company, Danaher Corporation, Evotec Ag, and The Jackson Laboratory.
There are other players in the early toxicity testing market which include Covance, CellSystems, BioQuanta, Epithelix, Celther Polska, and HemoGenix
Global Early Toxicity Testing Market Revenue, By Geography, 2014-2022 ($Million)
Asia-Pacific possesses high market potential for growth of early toxicity testing due to increase in demand for toxicity tests and upsurge in governmental initiatives to protect public health and environment. Progress in the research of in vitro and in silico technique has led to rapid developments in the toxicity testing products.
India Early Toxicity Testing Market, 2014-2022 ($Million)
Early toxicity testing market in India is projected to grow at a high CAGR of 13.2% during the forecast period. Asia-Pacific is experiencing fast-paced growth in terms of production and development of early toxicity testing products.
- This report entails detailed quantitative analysis of the current market trends for the period of 2014-2022 to identify the prevailing opportunities.
- The market estimations provided in the report are based on comprehensive analysis of the key developments in the industry.
- The global early toxicity testing market is comprehensively analyzed with respect to technique, end users, and geography.
- In-depth analysis based on geography helps understand the regional market to assist in strategic business planning.
- The development strategies adopted by key manufacturers are enlisted in the report to understand the competitive scenario of the market.
Early Toxicity Testing Market Key Segments
The global early toxicity testing market segmentation is explained below:
- In vivo
- In vitro
- Enzyme Toxicity Assays
- Bacterial Toxicity Assays
- Cell-Based ELISA and Western Blots
- Tissues Culture Assays
- Receptor Binding Assays
- Other Assays
By Toxicity End-points
- Dermal Toxicity
- Systemic Toxicity
- Ocular Toxicity
- Skin Sensitization and Irritation
- Organ Toxicity
- Other Toxicity Endpoints and Tests
- In silico
By End Users
- Pharmaceuticals industry
- Diagnostics industry
- Food industry
- Chemicals industry
- Cosmetics industry
- Other industries
- North America
- Rest of Europe
- Rest of Asia-Pacific
- Republic of South Africa
- Rest of LAMEA